Alzheimer’s disease (AD), characterized by the pathological accumulation of amyloid-β (Aβ) and hyperphosphorylated Tau proteins, remains a major global health challenge with limited therapeutic options. This evidence concerns the gene MAPT and Alzheimer disease.